Dear Hemophilia B Community, We are writing to share an important update on the availability of HEMGENIX® (etranacogene dezaparvovec-drlb). CSL is currently experiencing a temporary global...

New $1.5 billion investment builds on over $3 billion already spent on CSL's U.S. operations since 2018 Expansion will create at least 300 new jobs and enhance production of plasma-derived...

- 94% of patients (51 of 54) remained free from the burden of continuous prophylaxis treatment through five years following a single infusion of HEMGENIX, demonstrating sustained therapeutic...

Builds on company’s more than $3b U.S. investment since 2018 which created thousands of new jobs across 44 states

Could we all have lifelong robust immunity? Dr Carolien van de Sandt, Murdoch Children’s Research Institute, Melbourne Making proteins with AI: Dr Rhys Grinter, Bio21 Institute, The University...